Seagen and astellas announce initial results of padcev® (enfortumab vedotin-ejfv) in patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq:sgen) and astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d., “astellas”) today announced the initial results from cohort h of the ev-103 trial investigating padcev® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (mibc) who are ineligible for cisplatin-based chemotherapy. data from this late-breaking abstract will be included in an oral presentation (abstract 435) at th
SGEN Ratings Summary
SGEN Quant Ranking